Sees Q2 Adjusted EBITDA of $9M-$10M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy HCAT?
Sees Q2 adjusted EBITDA $9M-$10M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCAT
Wall Street analysts forecast HCAT stock price to rise
7 Analyst Rating
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 1.380
Low
2.75
Averages
3.85
High
5.00
Current: 1.380
Low
2.75
Averages
3.85
High
5.00
About HCAT
Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Health Catalyst Reports Strong Q1 2026 Earnings with Strategic Restructuring
- Strong Financial Performance: Health Catalyst reported total revenue of $70.8 million for Q1 2026, exceeding expectations, with adjusted EBITDA reaching $9.1 million, indicating robust growth in both revenue and profitability, thereby enhancing market confidence.
- Restructuring Initiative: The company announced a comprehensive operational and business restructuring called Project Nexus, expected to generate annualized savings of approximately $30 million, aimed at addressing client churn and revenue pressure through optimized resource allocation to enhance long-term competitiveness.
- Optimistic Outlook: Management anticipates total revenue for 2026 to be between $260 million and $265 million, with adjusted EBITDA projected at $30 million to $33 million, reflecting confidence in future performance despite facing short-term challenges.
- Client Churn Risks: While the company expects to retain at least $22 million of at-risk ARR, approximately $30 million remains at risk, highlighting the complexities of client transitions from DOS to Ignite that may lead to short-term revenue pressures.
See More
Health Catalyst Set to Announce Q1 Earnings on May 11
- Earnings Announcement Date: Health Catalyst (HCAT) is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimates at $0.02, reflecting a significant 100% year-over-year increase, while revenue is projected at $69.19 million, indicating a 12.9% decline, highlighting revenue challenges faced by the company.
- Historical Performance Review: Over the past two years, HCAT has only beaten EPS estimates 38% of the time and revenue estimates 75% of the time, reflecting volatility in profitability and revenue growth that could impact investor confidence moving forward.
- Estimate Revision Trends: In the last three months, HCAT has seen no upward revisions in EPS estimates, with five downward adjustments, while revenue estimates also faced no upward revisions and eight downward adjustments, indicating a persistent decline in market expectations for the company's future performance, which may pressure the stock price.
- Market Reaction: Following the recent earnings report, HCAT was downgraded by Wells Fargo, and the stock plummeted after mixed Q4 results, with the CEO not ruling out a potential sale, which may raise further concerns regarding the company's strategic direction among investors.
See More
Health Catalyst Shares Plunge 48.7% Amid Weak Demand
- Weak Performance: Health Catalyst reported billings of $71.98 million in Q4 with only a 4% year-on-year growth, indicating challenges in customer acquisition and retention due to increasing competition, which undermines investor confidence in future performance.
- Long Customer Acquisition Payback Period: The negative customer acquisition cost (CAC) payback period this quarter suggests that sales and marketing investments have not yielded expected returns, highlighting a lack of product differentiation in a highly competitive market.
- Cash Burn Raises Concerns: While the company posted positive free cash flow this quarter, its average free cash flow margin was negative 6.4% over the past year, indicating a significant cash drain that limits its ability to return capital to investors.
- Bleak Future Outlook: Although the stock trades at a forward price-to-sales ratio of 0.3, appearing cheap, the shaky fundamentals present substantial downside risks, prompting analysts to recommend seeking stocks with better growth potential.
See More
Health Catalyst Appoints New Board Member
- Leadership Change: Health Catalyst announced the appointment of Steve Nelson, Executive Vice President of Aetna, to its Board of Directors, effective May 1, 2026, reflecting the company's ongoing leadership transformation aimed at addressing challenges in cost, clinical outcomes, and consumer experience within healthcare systems.
- Rich Industry Experience: Nelson's tenure at Aetna provides him with a profound understanding of the U.S. healthcare ecosystem, having previously served as CEO of ChenMed and Duly Health and Care, where he championed value-based care models that enhance clinical quality and control costs.
- Clear Strategic Goals: His appointment is seen as a significant step for Health Catalyst in executing its strategic commitment to leverage AI-driven technology solutions that tackle foundational challenges faced by healthcare systems, thereby advancing the industry.
- Optimistic Market Outlook: Backed by $2.8 billion in documented outcomes and deep domain expertise, Health Catalyst aims to help healthcare systems transition from data to measurable action, with Nelson's addition expected to further strengthen the company's competitive position in the market.
See More
American Well Corporation Shares Surge 13.3% Amid Strong Q4 Outlook
- Significant Price Surge: American Well Corporation (AMWL) shares rallied 13.3% in the last trading session to close at $6.24, with notable trading volume indicating strong investor optimism regarding the company's future performance.
- Strong Financial Performance: The company reported fourth-quarter sales of $55.3 million, surpassing the Zacks Consensus Estimate by 5.3%, highlighting its robust growth potential in the digital healthcare sector, which may attract more investor interest.
- Future Expectations: Although a quarterly loss of $0.77 per share is anticipated, reflecting a year-over-year increase of 55.5%, revenues are expected to decline by 24.8% to $50.25 million, indicating cautious market sentiment regarding the company's future profitability.
- Market Trend Monitoring: Despite the consensus EPS estimate remaining unchanged over the past 30 days, the stock's upward movement may be linked to growing investor enthusiasm for AI-driven digital healthcare platforms, making AMWL's future performance worth monitoring.
See More
Market Volatility Following Anthropic's Managed Agents Announcement
- AI Disruption: Anthropic's announcement of Managed Agents has sparked investor concerns about potential disruptions to existing SaaS business models, leading to notable declines in stocks such as Doximity, Guidewire, and Intuit, which fell by 3%, 5%, and 5%, respectively.
- Overreaction in Market: Despite the severe market reaction to AI agents, analysts suggest that significant price drops may present buying opportunities for high-quality stocks, particularly as investors look for long-term value amidst volatility.
- Health Catalyst Volatility: Health Catalyst has experienced 51 moves greater than 5% over the past year, with its current share price at $1.03, representing a 77.3% decline from its 52-week high of $4.52, indicating cautious market sentiment regarding its future prospects.
- Geopolitical Tensions: Recent geopolitical tensions have escalated, pushing oil prices to new highs, which could increase business costs and trigger inflation, further impacting global economic growth, necessitating investor vigilance on related developments.
See More
Health Catalyst Reports Strong Q1 2026 Earnings with Strategic Restructuring
- Strong Financial Performance: Health Catalyst reported total revenue of $70.8 million for Q1 2026, exceeding expectations, with adjusted EBITDA reaching $9.1 million, indicating robust growth in both revenue and profitability, thereby enhancing market confidence.
- Restructuring Initiative: The company announced a comprehensive operational and business restructuring called Project Nexus, expected to generate annualized savings of approximately $30 million, aimed at addressing client churn and revenue pressure through optimized resource allocation to enhance long-term competitiveness.
- Optimistic Outlook: Management anticipates total revenue for 2026 to be between $260 million and $265 million, with adjusted EBITDA projected at $30 million to $33 million, reflecting confidence in future performance despite facing short-term challenges.
- Client Churn Risks: While the company expects to retain at least $22 million of at-risk ARR, approximately $30 million remains at risk, highlighting the complexities of client transitions from DOS to Ignite that may lead to short-term revenue pressures.
See More
Health Catalyst Set to Announce Q1 Earnings on May 11
- Earnings Announcement Date: Health Catalyst (HCAT) is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimates at $0.02, reflecting a significant 100% year-over-year increase, while revenue is projected at $69.19 million, indicating a 12.9% decline, highlighting revenue challenges faced by the company.
- Historical Performance Review: Over the past two years, HCAT has only beaten EPS estimates 38% of the time and revenue estimates 75% of the time, reflecting volatility in profitability and revenue growth that could impact investor confidence moving forward.
- Estimate Revision Trends: In the last three months, HCAT has seen no upward revisions in EPS estimates, with five downward adjustments, while revenue estimates also faced no upward revisions and eight downward adjustments, indicating a persistent decline in market expectations for the company's future performance, which may pressure the stock price.
- Market Reaction: Following the recent earnings report, HCAT was downgraded by Wells Fargo, and the stock plummeted after mixed Q4 results, with the CEO not ruling out a potential sale, which may raise further concerns regarding the company's strategic direction among investors.
See More
Health Catalyst Shares Plunge 48.7% Amid Weak Demand
- Weak Performance: Health Catalyst reported billings of $71.98 million in Q4 with only a 4% year-on-year growth, indicating challenges in customer acquisition and retention due to increasing competition, which undermines investor confidence in future performance.
- Long Customer Acquisition Payback Period: The negative customer acquisition cost (CAC) payback period this quarter suggests that sales and marketing investments have not yielded expected returns, highlighting a lack of product differentiation in a highly competitive market.
- Cash Burn Raises Concerns: While the company posted positive free cash flow this quarter, its average free cash flow margin was negative 6.4% over the past year, indicating a significant cash drain that limits its ability to return capital to investors.
- Bleak Future Outlook: Although the stock trades at a forward price-to-sales ratio of 0.3, appearing cheap, the shaky fundamentals present substantial downside risks, prompting analysts to recommend seeking stocks with better growth potential.
See More
Health Catalyst Appoints New Board Member
- Leadership Change: Health Catalyst announced the appointment of Steve Nelson, Executive Vice President of Aetna, to its Board of Directors, effective May 1, 2026, reflecting the company's ongoing leadership transformation aimed at addressing challenges in cost, clinical outcomes, and consumer experience within healthcare systems.
- Rich Industry Experience: Nelson's tenure at Aetna provides him with a profound understanding of the U.S. healthcare ecosystem, having previously served as CEO of ChenMed and Duly Health and Care, where he championed value-based care models that enhance clinical quality and control costs.
- Clear Strategic Goals: His appointment is seen as a significant step for Health Catalyst in executing its strategic commitment to leverage AI-driven technology solutions that tackle foundational challenges faced by healthcare systems, thereby advancing the industry.
- Optimistic Market Outlook: Backed by $2.8 billion in documented outcomes and deep domain expertise, Health Catalyst aims to help healthcare systems transition from data to measurable action, with Nelson's addition expected to further strengthen the company's competitive position in the market.
See More
American Well Corporation Shares Surge 13.3% Amid Strong Q4 Outlook
- Significant Price Surge: American Well Corporation (AMWL) shares rallied 13.3% in the last trading session to close at $6.24, with notable trading volume indicating strong investor optimism regarding the company's future performance.
- Strong Financial Performance: The company reported fourth-quarter sales of $55.3 million, surpassing the Zacks Consensus Estimate by 5.3%, highlighting its robust growth potential in the digital healthcare sector, which may attract more investor interest.
- Future Expectations: Although a quarterly loss of $0.77 per share is anticipated, reflecting a year-over-year increase of 55.5%, revenues are expected to decline by 24.8% to $50.25 million, indicating cautious market sentiment regarding the company's future profitability.
- Market Trend Monitoring: Despite the consensus EPS estimate remaining unchanged over the past 30 days, the stock's upward movement may be linked to growing investor enthusiasm for AI-driven digital healthcare platforms, making AMWL's future performance worth monitoring.
See More
Market Volatility Following Anthropic's Managed Agents Announcement
- AI Disruption: Anthropic's announcement of Managed Agents has sparked investor concerns about potential disruptions to existing SaaS business models, leading to notable declines in stocks such as Doximity, Guidewire, and Intuit, which fell by 3%, 5%, and 5%, respectively.
- Overreaction in Market: Despite the severe market reaction to AI agents, analysts suggest that significant price drops may present buying opportunities for high-quality stocks, particularly as investors look for long-term value amidst volatility.
- Health Catalyst Volatility: Health Catalyst has experienced 51 moves greater than 5% over the past year, with its current share price at $1.03, representing a 77.3% decline from its 52-week high of $4.52, indicating cautious market sentiment regarding its future prospects.
- Geopolitical Tensions: Recent geopolitical tensions have escalated, pushing oil prices to new highs, which could increase business costs and trigger inflation, further impacting global economic growth, necessitating investor vigilance on related developments.
See More
